Possibility of paclitaxel as an alternative radiosensitizer to 5-fluorouracil for colon cancer

Oncology Reports

Volumn 24, Issue 4, 2010, Pages 1029-1034

  Hiro, Junichiro ^a   Inoue, Yasuhiro ^a   Toiyama, Yuji ^a   Yoshiyama, Shigeyuki ^a   Tanaka, Koji ^a   Mohri, Yasuhiko ^a   Miki, Chikao ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Colon cancer; Paclitaxel; Radiosensitivity

Indexed keywords

BUB1 RELATED PROTEIN; CELL CYCLE PROTEIN; CHECKPOINT KINASE 1; FLUOROURACIL; PACLITAXEL; PROTEIN MAD2; UNCLASSIFIED DRUG; WEE1 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; COLON CANCER; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IRRADIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RADIATION DOSE; RADIOSENSITIVITY; RADIOSENSITIZATION; WESTERN BLOTTING;

EID: 77957355398     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000951     Document Type: Article

References (39)

1. Bernier J, Cooper JS, Pajak TF, et al: Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 27: 843-850, 2005.
2. Pignon JP, Arriagada R, Ihde DC, et al: A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 327: 1618-1624, 1992.
3. Herskovic A, Martz K, Al-Sarraf M, et al : Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326: 1593-1598, 1992.
4. Bleiberg H, Goffin JC, Dalesio O, et al: Adjuvant radiotherapy and chemotherapy in respectable gastric cancer: a randomised trial of the gastrointestinal tract cancer co-operative group of the EORTC. Eur J Surg Oncol 15: 535-543, 1989.
5. Colorectal Cancer Collaborative Group: Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet 358: 1291-1304, 2001.
6. Davis MA, Tang HY, Maybaum J and Lawrence TS: Dependence of fluorodeoxyuridine-mediated radiosensitization on S phase progression. Int J Radiat Biol 67: 509-517, 1995.
7. Miller EM and Kinsella TJ: Radiosensitization by fluorodeoxyuridine: effects of thymidylate synthase inhibition and cell synchronization. Cancer Res 52: 1687-1694, 1992.
8. Rich TA, Shepard RC and Mosley ST: Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 22: 2214-2232, 2004.
9. Mohiuddin M, Winter K, Mitchell E, et al: Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 24: 650-655, 2006.
10. Parmar MK, Ledermann JA, Colombo N, et al: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099-2106, 2003.
11. Kümmel S, Krocker J, Kohls A, et al: Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Br J Cancer 94: 1237-1244, 2006.
12. Moore DH, Blessing JA and McQuellon RP: Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 22: 3113-3119, 2004.
13. Chu Q, Vincent M, Logan D, Mackay JA and Evans WK: Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer 50: 355-374, 2005.
14. Schiff PB and Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565, 1980.
15. Choy H, Rodriguez FF, Koester S, Hilsenbeck S and von Hoff DD: Investigation of taxol as a potential radiation sensitizer. Cancer 71: 3774-3778, 1993.
16. Leonard CE, Chan DC, Chou TC, Kumar R and Bunn PA: Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res 56: 5198-5204, 1996.
17. Rodriguez M, Sevin BU, Perras J, et al: Paclitaxel: a radiation sensitizer of human cervical cancer cells. Gynecol Oncol 57: 165-169, 1995.
18. Niero A, Emiliani E, Monti G, et al: Paclitaxel and radiotherapy: sequence-dependent efficacy - a preclinical model. Clin Cancer Res 5: 2213-2222, 1999.
19. Lövey J, Fazekas K, Ladányi A, Németh G and Tímár J: Low-dose irradiation and short-exposure suboptimal-dose paclitaxel adversely modulate metastatic potential of squamous carcinoma cells. Strahlenther Onkol 179: 812-818, 2003.
20. Einzig AI, Neuberg D, Wiernik PH, et al: Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy: an Eastern Cooperative Oncology Group Trial (PA286). Am J Ther 3: 750-754, 1996.
21. Kusunoki M, Yanagi H, Kotera H, Noda M and Yamamura T: Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression. Int J Oncol 13: 653-657, 1998.
22. Kusunoki M, Yanagi H, Noda M, Yoshikawa R and Yamamura T: Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. Cancer 89: 1228-1235, 2000.
23. Yoshikawa R, Kusunoki M, Yanagi H, et al: Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 61: 1029-1037, 2001.
24. Sinclair W: Cyclic X-ray responses in mammalian cells in vitro. Radiat Res 33: 620-643, 1968.
25. Price LA and Hill BT: A kinetically based logical approach to the chemotherapy of head and neck cancer. Clin Otolaryngol 2: 339-345, 1977.
26. Minarik L and Hall EJ: Taxol in combination with acute and low dose rate irradiation. Radiother Oncol 32: 124-128, 1994.
27. Wani MC, Taylor HL, Wall ME, Coggon P and McPhail AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93: 2325-2327, 1971.
28. Rowinsky EK, Donehower RC, Jones RJ and Tuker RW: Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 48: 4093-4100, 1998.
29. O'Connor PM, Jackman J, Bae I, et al: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300, 1997.
30. Wahl AF, Donaldson KL, Fairchild C, et al: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2: 72-79, 1996.
31. Liebmann J, Cook JA, Fisher J, Teague D and Mitchell JB: In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 86: 441-446, 1994.
32. Liebmann J, Cook JA, Fisher J, Teague D and Mitchell JB: Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol). Int J Radiat Oncol Biol Phys 29: 559-564, 1994.
33. Liu Q, Guntuku S, Cui XS, et al: Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14: 1448-1459, 2000.
34. Sanchez Y, Bachant J, Wang H, et al: Control of the DNA damage checkpoint by chk1 and rad53 protein kinases through distinct mechanisms. Science 286: 1166-1171, 1999.
35. Lee J, Kumagai A and Dunphy WG: Positive regulation of Wee1 by Chk1 and 14-3-3 proteins. Mol Biol Cell 12: 551-563, 2001.
36. McGowan CH and Russell P: Cell cycle regulation of human Wee1. EMBO J 14: 2166-2175, 1995.
37. Inoue Y, Tanaka K, Hiro J, et al: In vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer. Int J Oncol 28: 479-486, 2006.
38. Huang TS, Shu CH, Chao Y, Chen SN and Chen LL: Activation of MAD 2 checkprotein and persistence of cyclin B1/CDC 2 activity associate with paclitaxel-induced apoptosis in human nasopharyngeal carcinoma cells. Apoptosis 5: 235-241, 2000.
39. Sudo T, Nitta M, Saya H and Ueno NT: Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 64: 2502-2508, 2004.